Drug
Vistusertib clinical trials
Also written AZD2014.
- studies test it
- 28
- open now
- 1
- in phase 3
- 0
- first study started
- 2009
Keep track of what changes. Save the vistusertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AZD2014
- 29
Studies by the year they started
28 studies that test it; most in 2016 (6)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 18
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 20
AstraZeneca (7) · Samsung Medical Center (5) · Queen Mary University of London (3) · UNICANCER (2) · Massachusetts General Hospital (2) · M.D. Anderson Cancer Center (1) · Centre Leon Berard (1) · University of Birmingham (1)
Often tested with
Tested in the same studies.
AZD 6244 (6) · Durvalumab (5) · Olaparib (5) · Capivasertib (5) · AZD4547 (4) · Ceralasertib (3) · Adavosertib (2) · Danvatirsen (2)
Studies
Open first, then newest update. How each study uses vistusertib is read from its arms, and is right about nine times in ten.
Testing it · 28
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Vistusertib
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingPhase 1AstraZenecaNCT02546661Written as Vistusertib
- mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02208375Written as Vistusertib
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935Written as Vistusertib
- AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast CancerCompletedPhase 1AstraZenecaNCT01597388Written as AZD2014
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingPhase 2AstraZenecaNCT03334617Written as Vistusertib
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as AZD2014
- Japanese Phase I Study of AZD2014 in Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT02398747Written as AZD2014
- A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerCompletedPhase 2Queen Mary University of LondonNCT02216786Written as AZD2014
- A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.CompletedPhase 1Royal Marsden NHS Foundation TrustNCT02193633Written as AZD2014 3 on/4 off & weekly paclitaxel
- Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast CancerCompletedPhase 1AstraZenecaNCT02599714Written as AZD2014
- Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)Active, not recruitingPhase 1/2Centre Leon BerardNCT02730923Written as AZD2014
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedPhase 2UNICANCERNCT02117167Written as AZD2014
- Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid TumorsTerminatedPhase 1/2National Cancer Institute (NCI)NCT03366103Written as Vistusertib
- mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma MultiformeCompletedPhase 1Canadian Cancer Trials GroupNCT02619864Written as AZD2014
- Vistusertib (AZD2014) For Recurrent Grade II-III MeningiomasStatus unknownPhase 2Massachusetts General HospitalNCT03071874Written as AZD2014
- AZD2014 In NF2 Patients With Progressive or Symptomatic MeningiomasCompletedPhase 2Massachusetts General HospitalNCT02831257Written as AZD2014
- A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell MalignanciesTerminatedPhase 1/2Acerta Pharma BVNCT03205046Written as vistusertib
- A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced CancersStatus unknownPhase 1/2Queen Mary University of LondonNCT02583542Written as AZD2014
- Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate CancerCompletedPhase 1Cambridge University Hospitals NHS Foundation TrustNCT02064608Written as AZD2014
See all 28 studies that test vistusertib →
Given in every arm · 2 — vistusertib is usual care beside what is tested
- An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedPhase 2University of BirminghamNCT02752204Written as AZD 2014
- Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose PhaseCompletedPhase 1AstraZenecaNCT02640755Written as [14C]AZD2014
As the comparator · 1 — what is tested is compared with vistusertib
Codes
What other systems call vistusertib · ClinicalTrials.gg INT006406
- MeSH (NLM) C585537vistusertibOne source NLM
- UNII (FDA) 0BSC3P4H5XVISTUSERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27089147vistusertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88329VistusertibOne source FDA
- DrugBank DB11925One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585537 | vistusertib | One source NLM |
| UNII (FDA) | 0BSC3P4H5X | VISTUSERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089147 | vistusertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88329 | Vistusertib | One source FDA |
| DrugBank | DB11925 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.